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Objectives: This study outlines the needs and current development of the “fourth hurdle”
(i.e., requirement of effectiveness and cost-effectiveness data for drug coverage policy
decisions) in Hungary, describes the legal background and seeks to address some of the
most important questions in this field.
Methods: The study draws on international experiences and discusses five issues that a
given jurisdiction needs to consider before introducing the “fourth hurdle” for
pharmaceuticals.
Results: The “fourth hurdle” is very relevant in Hungary because many existing drugs are
unevaluated and many new, expensive drugs are becoming available. On the other hand,
the existing resources for health technology assessment, including economic evaluation,
are quite limited. All the five issues are relevant in the Hungarian setting and were helpful
in determining exactly how the “fourth hurdle” should be applied.
Conclusions: The most important issue seems to be that the implementation of the
“fourth hurdle” needs to be achieved in a way consistent with the limited resources for HTA
in Hungary. Specifically this means that, in setting priorities for drugs to evaluate,
additional criteria need to be applied. In particular, priority should be given to assessing
drugs that have been evaluated in other countries, because this affords the opportunity to
adapt existing studies or models to the Hungarian situation.
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Several countries have already introduced the “fourth hur-
dle,” namely a requirement for cost-effectiveness evidence
before reimbursement of new drugs. The first three hurdles,
which already exist in most countries, require the demonstra-
tion of efficacy, safety, and quality of the manufacturing pro-
cess. Countries considering introducing the “fourth hurdle”
can learn from the experiences of others. This is partic-
ularly important for smaller countries, such as Hungary,
where resources for the evaluation of health technologies
may be in short supply. Hungary has moved toward introduc-
ing the “fourth hurdle” for pharmaceuticals since the pub-
lication of the Hungarian guidelines for economic evalua-
tion in 2002 (11). This development is well supported by
the Act No. CLIV of 1997 on Health, which clearly states
among the basic principles (Title 2. paragraph 2 point 5)
that health care services have to be evidence based and cost-
effective.
This study outlines the needs and current development
of this new requirement in Hungary, describes the legal back-
ground and seeks to address some of the most important
questions in this field. The study draws on international ex-
periences and discusses five issues that a given jurisdiction
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needs to consider before introducing the “fourth hurdle” for
pharmaceuticals.
These five issues are (i) Should evidence be requested for
all new drugs, or just some? (ii) How should drugs be priori-
tized for assessment? (iii) Should data from other countries
be accepted? If so which? (iv) Should an independent assess-
ment be made of the evidence, including company submis-
sions?(v)Shouldatwo-stageappraisalprocessbeconsidered?
Answers are suggested for these questions, consistent
with what can realistically be achieved within current re-
sources, in a country where only eighteen economic evalu-
ations have been conducted and published during the past
10 years. We believe that the issues, challenges, and possible
solutions related to the “fourth hurdle” in Hungary are rele-
vant and generalizable to the other new member states of the
European Union.
THE HUNGARIAN CONTEXT
The first three hurdles (quality, safety, and efficacy) are ap-
plied in Hungary in a manner similar to other European Union
member states, through the registration procedure. A phar-
maceutical product can be marketed only if it is registered
and a permit for marketing has been obtained. Registration
is the responsibility of the National Institute of Pharmacy
(Orsza´gos Gyo´gyszere´szeti Inte´zet, OGYI). The National In-
stitute of Pharmacy (NIP) is a state owned agency, which
both registers products and issues permits for marketing. The
NIP accepts the drug approvals of the U.S. Food and Drug
Administration (for normal procedure) and the European
Agency for the Evaluation of Medicinal Products (for cen-
tralised European procedure). The duration of the registration
procedure varies widely, taking 2 years (for normal proce-
dure), 1 year (for decentralised procedure), and 3 months
(for centralised European procedure). The NIP does not con-
duct pharmaco-economic studies, as these are not part of the
registration procedure. Subsequent price negotiations, with
the National Health Insurance Fund Administration (NHIFA)
precede market introduction. Permits for distribution are ap-
proved by the Chief Medical Officer (6).
Some authors categorize effectiveness under the third
hurdle (efficacy). However, clinical trials for drug registration
provide efficacy and safety data, but are usually inadequate to
address real-world decision making about treatments in a par-
ticular country, or in a particular setting. Health technology,
for instance drug therapy, with demonstrated efficacy based
on clinical trials, may not be effective outside of the con-
trolled conditions of the trial (10;13). Therefore, it is likely
that the effectiveness data required for the fourth hurdle will
extend beyond those presented for drug registration.
RESULTS
Based on this understanding of the Hungarian context, the
five issues are now explored in turn.
Should Evidence be Requested for All New
Drugs, or Just Some?
Australia requires economic submissions from manufactur-
ers relating to all new drugs to be used outside public hospi-
tals, as does Ontario (3;7;8,16). In contrast, The Netherlands
only requires submissions for drugs outside the reference
price system. Both Portugal and the United Kingdom are also
quite selective regarding which drugs they subject to detailed
appraisal.
One important factor is the availability of financial and
human resources to undertake economic evaluations and to
assess their quality. Also, the use of economic evaluation
for some or all drugs needs to be viewed in the context
of other pharmaceutical policies operating in the country
concerned, for example, promotion of generic substitution,
reference pricing, prescribing audits and so on.
From a Hungarian perspective it is important to define
the term “new drug” from a practical point of view. Drugs fall
into the “new drug” category when they first require coverage
from the National Health Insurance Fund, or when requests
are made to change the indications, the population covered,
or the percentage of the subsidy. This is irrespective of how
old or new the particular drug is. In Hungary, the number of
available drugs at least partly covered by the health insurance
increased greatly over the past 10 to 15 years. A sufficient
evaluation capacity is needed for economic evaluation, so it is
important to determine (realistically) what capacity would be
considered as “sufficient” in Hungary for undertaking drug
evaluations.
Taking the example of the National Institute of Clinical
Excellence (NICE) in the United Kingdom, fifty appraisals
were published in the first 3 years, in which seventy-four
different drugs, ninety-four medical devices, fifteen clinical
procedures, and forty different clinical conditions were eval-
uated. According to Buxton (2), “this is an impressive start
but merely a scratch on the surface.” Buxton also stated that
“NICE estimates its guidance to have the potential to increase
costs to the NHS (in England and Wales) by approximately
575 million English Pounds.” Questions to be answered and
lessons to be learned from the example of NICE are as fol-
lows: what capacity for appraisal seems to be realistic in the
coming years in Hungary and what should be done about
implementation of the results of health economic studies?
Capacity Issues. As was discussed above, a large
number of drugs (and medical devices, clinical procedures,
and clinical conditions) could potentially be evaluated. Al-
though the number of drugs is numerous, the truly innova-
tive compounds seeking insurance coverage do not exceed
more than 5 to 10 drugs per year in Hungary. On one hand,
this seems to be a manageable number for economic evalu-
ation, but on the other hand, the available evidence relating
to these drugs is sometimes limited and thus their evaluation
is sometimes the most challenging. In assessing the capac-
ity to undertake economic evaluations, we need to address
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the total budget available, the human resources in terms of
trained evaluators, the availability of data, and the capacity
of the health care system to use the results. Taking all these
factors into account, it is anticipated that it will be possible
to undertake around ten appraisals per year.
Affordability Issues. It was mentioned above that
there is a potential to increase costs to the NHS (in England
and Wales) by approximately £575 million as a result of the
NICE guidelines. The Hungarian HTA agency (HunHTA) has
a more limited mandate, than NICE. Guidance is not manda-
tory, nor is a positive budgetary impact expected or planned
for. This suggests that those agencies issuing guidance on
the reimbursement or use of drugs in Hungary need to be
mindful of the budgetary impact. In part this might be han-
dled by the selection of drugs for assessment, as discussed
below.
How Should Drugs be Prioritized
for Assessment?
In cases where only certain drugs are appraised from an eco-
nomic perspective, decisions are required on which to ap-
praise (12;15). The most obvious criteria are: (i) drugs that
tackle important health problems; and (ii) drugs that are likely
to have a large budgetary impact. NICE considers appraising
technologies that are likely to have a “major impact on the
NHS.”
In Hungary, the intention is to use criteria similar to
those applied by NICE. However, these criteria are very dif-
ficult to quantify and use in practice, due to the fact that
no valid information source is available in Hungary relat-
ing to the morbidity and mortality pattern of the population.
More evaluations and better databases (disease registers have
just been created) need to be in place to identify a particular
health problem, and the extent of the burden it creates. The
“National Public Health Programme 2001–2010” does not
help too much; nineteen priority categories are listed, but the
public health items and the expected benefit are not specified
in detail (17). The additional factor in the Hungarian situation
is the very limited capacity for conducting health economics
analyses. Therefore, drugs should be assessed which satisfy
the following criteria:
The Availability of Published Reports of Eco-
nomic Analyses. Economic evaluation in Hungary is
likely to be much more feasible if a published HTA report or
economic analysis is available on the particular drugs from
guaranteed high quality sources; for instance reports from
INAHTA agencies or the Cochrane Collaboration. If a re-
port already exists, it can be adapted using available local
data. If no published HTA reports are available, the particu-
lar drug should not be assessed, unless there is a clear policy,
political requirement, or other important circumstances. The
lack of existence of a report probably means that the topic
(drug) is not recognized as high priority in the countries where
INAHTA agencies exist, or on the contrary, an important topic
Table 1. The market share of Top 25 agents (rank order) with
the highest health insurance subsidies (2002)
Top agents with Health insurance Percentage of the total
the highest health subsidies budget for drug
insurance subsidies (Billion HUF) subsidies
Top-05 24,2 Ft 12,63%
Top-10 39,9 Ft 20,78%
Top-15 52,4 Ft 27,34%
Top-20 63,8 Ft 33,24%
Top-25 73,9 Ft 38,52%
where not enough evidence available. Given the shortage of
professionals and HTA budget in the current stage of the HTA
development in Hungary, attempting to produce the first anal-
ysis worldwide is not recommended.
Known Clinical Relevance (Endpoint as Real
Outcome). As mentioned earlier, Drummond (4) argued
that the key component for economic studies is the underly-
ing evidence of clinical effectiveness, which means that end-
points from the study relate to real clinical improvements. If
this is not the case, and surrogate outcomes are used as the
endpoint of the clinical study, economic analysis should have
low priority.
Budget Impact Threshold for Economic Evalua-
tion. If the estimated budgetary impact of the particular drug
is greater than the 1 percent or 2 percent of the total drug bud-
get in the coming 2 to 5 years, economic analysis might be
initiated. (Similarly, in Australia if the estimated budgetary
impact is bigger than Aus $2 million, a special committee
decision is needed in addition to the standard procedure).
As Table 1 shows, a relatively small number of drugs with
health insurance subsidies represent a significant percentage
of the total budget for drug subsidies. Economic analysis
might be particularly beneficial in this group of agents.
Analyzing the agents with the highest health insurance
subsidies shows that even the agent in 25th place has a market
share of 1 percent. The Top-10 agents have a total market
share of 20.78 percent, while the Top-25 agents have 38.52
percent. These data suggest that evaluation of 25 agents would
cover a substantial proportion of the total health insurance
subsidies for drugs.
Should Data From Other Countries be
Accepted? If so Which?
It is generally considered that clinical data for health tech-
nologies are transferable from location to location, although
in all countries we encounter the problem that data from Phase
III clinical trials may not reflect the effectiveness of the drug
in regular clinical practice. Setting this problem aside, clini-
cal data from another country are usually acceptable, unless
the patients enrolled in the trial, or the regimens compared,
are different from those that would apply in the country of in-
terest. Data on practice patterns, and hence resource use, are
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likely to be less transferable and some additional data col-
lection in the country of interest is likely to be required, if
only to check that data from another country are relevant.
It is almost certain that unit cost or price data from another
country will not apply and these should be collected for the
country of interest (14). The case for new data collection of
health state preference values (or utilities) is less clear. NICE
requires that the preferences should be relevant for the pop-
ulation of England and Wales, but this does not necessarily
mean that preference values from elsewhere are not relevant.
The issue of transferability of economic data is crucial for
small middle income countries where the capacity for un-
dertaking health economic analysis is limited. This has been
discussed by Rutten and Gula´csi (14), who highlighted the
most important items that need to be taken into consideration.
Clinical and Epidemiological Data. Clinical data
can usually be considered to be transferable, especially within
Europe, because no significant genetic or other differences
exist among European nations. However, incidence and age-
standardized incidence of various lifestyle-related diseases
might differ. These might include lung cancer and cancers of
mouth (smoking), some cardiovascular diseases (eating too
much fat and not having enough exercise), and the incidence
of those diseases which are dependent on GDP per capita
(environmental exposures, working and housing conditions,
health care services). Incidence of a given disease might be
the same in different countries, but prevalence (especially the
detected and documented prevalence) might be different due
to various reasons. To know the size of the target population
is crucial to estimate the potential impact of the drug on the
health of the population and to calculate the budget impact.
Resource Utilization, Costs, and Cost-
Effectiveness. Because practice patterns, resource
availability, and prices vary from country to country, these
data are generally not transferable. There might also be
considerable differences in willingness to pay and ability
to pay for health benefits among countries. The same may
be true of the health utility values as well. Therefore, in
principle, it may be necessary to repeat economic evaluations
in different countries. However, one should be aware of the
fact that pharmaceutical companies might not repeat cost
and cost-effectiveness studies in all countries, especially not
in small countries when the potential market is less then 10
or even 5 million population. Therefore, a requirement to
produce country-specific studies would not be very realistic.
One practical way forward would be to use an economic
model created in one country, populated with local data in
another country. However, economic models are often sub-
mitted by companies to the appraisal committees under con-
ditions of “commercial-in-confidence,” and, therefore, im-
portant details are removed from the published version of the
appraisal report. Also, models are often “home made,” by
researchers and not created for public use. In particular, they
usually do not have good documentation. Often models are
considered to be the “intellectual property” of the researchers
and the developers usually wish to publish academic papers
before making details publicly available (see below).
Should an Independent Assessment be
Made of Evidence, Including Company
Submissions?
In all countries operating a fourth hurdle, assessments are
made of the relevant evidence on cost-effectiveness as part
of the decision-making process. An important component
of the evidence is contained in submissions from manufac-
turers and sponsors of the health technologies concerned.
Whilst these often contain high quality analyses from con-
sultants or academic researchers funded by the company,
submissions should be viewed as advocacy for the prod-
uct (i.e., attempts to show the product in the best possible
light). The lengths to which various jurisdictions go to as-
sess the evidence in company submissions varies greatly. In
some places, especially the smaller countries, the assessments
are undertaken in-house, within the Ministry or drug reim-
bursement agency. In other jurisdictions the in-house staff
are supported by a committee of academic economists and
health service researchers who also assess the submissions
(e.g., in Australia).
At the other end of the spectrum, organizations like NICE
in the United Kingdom commission their own independent
assessment of the evidence from academic research centres.
These technology assessment reviews include not only an as-
sessment of the company submissions, but also meta-analyses
of the clinical literature and additional economic models.
Should a Two-Stage Appraisal Process
be Considered?
The main argument in favor of a two-stage process is that,
at the time of launch of a new drug, very little is known
about its long-term benefits when used in regular clinical
practice. Therefore, the initial economic assessment has to
be based on efficacy data from Phase III clinical studies, per-
haps augmented by modelling. In some countries the existing
arrangements already provide for the possibility of gathering
additional data and/or a review of guidance at a later date
(e.g., 3 years). On an intellectual level this makes a lot of
sense. The main difficulties are practical ones. For exam-
ple, if the new drug is approved for reimbursement, will the
sponsoring company be willing to consider further random-
ized controlled trials? Who will pay for the studies, including
the study drug, post-reimbursement? How feasible would it
be to remove a drug from the reimbursement list, or at least
restrict its use, should the longer-term data be unimpressive?
On the other hand, the longer-term cost-effectiveness results
may be more impressive if clinicians learn to target the drug
effectively, or obtain satisfactory therapeutic results by using
a lower dose than was used in the clinical trials. In principle,
a risk-sharing deal is one way around some of the difficulties
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outlined above. An example of one such deal is the agreement
in the UK between the government and the manufacturers of
beta interferon for multiple sclerosis. In this case NICE was
skeptical about some of the long-term outcomes, in partic-
ular the clinical outcomes for patients who have to discon-
tinue therapy. After much argument, the government decided
to allow treatment for certain categories of patients, at the
drug price requested by the manufacturers. However, it in-
tends to monitor the long-term progress of patients and may
ask the companies to return some of the income they receive
from sales of the drugs if the results are less impressive than
claimed (1). This is a very promising drug coverage option
in Hungary, in cases where the patient population is small,
the clinical outcome is well defined and the treatment process
itself is well controlled. These criteria apply for those drugs
that are covered by a special budget, in accredited hospitals,
administered by named and accredited provider organiza-
tions and doctors, using defined clinical protocols on named
patients.
DISCUSSION AND CONCLUSIONS
Consideration of the five issues has proven a useful exercise
in the Hungarian context. The most important issue seems
to be that the implementation of the fourth hurdle needs to
be achieved in a way consistent with the limited resources
for HTA in Hungary. Specifically this means that, in setting
priorities for drugs to evaluate, additional criteria need to be
applied. In particular, priority should be given to assessing
drugs that have been evaluated in other countries, because
this affords the opportunity to adapt existing studies or mod-
els to the Hungarian situation. Therefore, the methodological
priority is to develop, and further refine, the approaches for
adapting economic data from one location to another. Adapta-
tion will also be greatly assisted if commercial-in-confidence
restrictions are relaxed.
The obvious need for countries like Hungary to collab-
orate with other countries in the European Union begs the
question of whether there will ever be a centralized proce-
dure for drug reimbursement within the EU, to mirror that
for drug licensing. This is clearly a possibility in the future,
but several commentators (5;9) have pointed out that there
are several hurdles to be overcome.
Perhaps the experience of countries like Hungary, in
adapting studies from elsewhere, and collaborating with re-
searchers and ministry officials in overseas countries may
help identify the main methodological and practical issues
that need to be resolved before EU harmonization can take
place.
POLICY IMPLICATIONS
New policies concerning the reimbursement diffusion and
use of health technologies are often developed in isolation.
By using the example of introducing the “fourth hurdle” for
pharmaceuticals, this study illustrates that it is possible to
learn from other countries’ experiences, yet still apply new
policies in ways that best suit the local circumstances. The
process of learning from others is particularly important in
countries with limited resources for health technology assess-
ment.
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